FlawCheck Citator
Check how courts have cited this case. Use our free citator for the most current treatment.
No. 10655866
United States Court of Appeals for the Ninth Circuit

United States v. Alvear

No. 10655866 · Decided August 18, 2025
No. 10655866 · Ninth Circuit · 2025 · FlawFinder last updated this page Apr. 2, 2026
Case Details
Court
United States Court of Appeals for the Ninth Circuit
Decided
August 18, 2025
Citation
No. 10655866
Disposition
See opinion text.
Full Opinion
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS AUG 18 2025 MOLLY C. DWYER, CLERK U.S. COURT OF APPEALS FOR THE NINTH CIRCUIT UNITED STATES OF AMERICA, No. 24-6242 D.C. No. Plaintiff - Appellee, 2:20-cr-00229-CDS-MDC-1 v. MEMORANDUM* WILLIAM ALVEAR, Defendant - Appellant. Appeal from the United States District Court for the District of Nevada Cristina D. Silva, District Judge, Presiding Argued and Submitted August 12, 2025 Pasadena, California Before: NGUYEN, FORREST, and VANDYKE, Circuit Judges. Appellant-Defendant William Alvear (“Alvear”) was caught on film during three separate controlled buys staged by the Federal Bureau of Investigations (“FBI”) distributing and prescribing controlled substances to two confidential human sources. A jury convicted him for three counts of distribution of a controlled substance (Schedule II) in violation of 21 U.S.C. §§ 841(a)(1) & * This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3. (b)(1)(C) and five counts of distribution of a controlled substance in violation of 21 U.S.C. §§ 841(a)(1) & (b)(1)(C) (Schedule IV). Alvear moved for acquittal and a new trial on the grounds of insufficient evidence and entrapment, which the district court denied. We have jurisdiction under 28 U.S.C. § 1291, and we affirm. 1. “We review the district court’s denial of a motion for acquittal in the same manner as a challenge to the sufficiency of the evidence.” United States v. Ladum, 141 F.3d 1328, 1337 (9th Cir. 1998). Sufficiency of the evidence is a “two-step inquiry” asking “whether ‘after viewing the evidence in the light most favorable to the prosecution, any rational trier of fact could have found the essential elements of the crime beyond a reasonable doubt.’” United States v. Nevils, 598 F.3d 1158, 1163–64 (9th Cir. 2010) (en banc) (quoting Jackson v. Virginia, 443 U.S. 307, 319 (1979)). Under 21 U.S.C. § 841(a)(1), it is a federal crime “[e]xcept as authorized . . . for any person knowingly or intentionally . . . to manufacture, distribute, or dispense” a controlled substance. A violation under § 841(a)(1) requires the government to prove that that the doctor knew or intended that the prescription was unauthorized. Ruan v. United States, 597 U.S. 450, 468 (2022). The evidence presented to the jury is sufficient to establish both that the prescriptions were unauthorized and that Alvear knew. Dr. Timonthy Munzing, testifying as an expert on lawful medical and prescription practices, opined that 2 24-6242 Alvear’s meeting with the confidential sources fell “far below the floor” of the standard of care doctors should provide their patients if they are seeking to prescribe medication for legitimate purposes. He pointed out that Alvear failed to conduct medical examinations or review the patient histories of either source, that the reasons the sources provided for needing prescriptions were unreliable and did not warrant pain medication, and that Alvear accepted “tips” and appeared to negotiate for money in exchange for prescriptions. Leo Basch, a pharmacist and expert in the distributing and dispensing of controlled substances, told the jury that Alvear failed to perform the mandatory database check to ensure the sources were not being overprescribed narcotics. Basch also pointed out that when Alvear handed the sources alprazolam, otherwise known as Xanax, during his meetings with them, the drugs were not formally dispensed and often the sources provided no medical reason for wanting the drug. This is sufficient evidence for a jury to conclude the medication distributions were unauthorized. See Ruan, 597 U.S. at 467. Because Alvear failed to perform basic reviews of the sources’ medical history or give them formal examinations, a jury could easily conclude that he was aware there was no medical basis for providing the drugs. See United States v. Beecroft, 608 F.2d 753, 757 (9th Cir. 1979) (“Intent need not be established by direct evidence, but may be inferred from the defendant’s statements and 3 24-6242 conduct.”). The footage from the sting operation also showed Alvear repeatedly telling the sources that they did not need medication, yet he still provided prescriptions and loose pills. Alvear additionally acted to conceal his conduct— indicating that he knew it was criminal—by instructing the sources to go to certain pharmacies that were unlikely to raise a warning about the prescription. There is more than sufficient evidence to support the guilty verdict. 2. The same standard for evaluating the sufficiency of the evidence supports a jury’s conclusion that a defendant was not entrapped. United States v. Poehlman, 217 F.3d 692, 698 (9th Cir. 2000). “To raise entrapment, [a] defendant need only point to evidence from which a rational jury could find that he was induced to commit the crime but was not otherwise predisposed to do so.” Id. Sufficient evidence supports the jury’s rejection of Alvear’s defense on either lack of inducement or predisposition. See United States v. McClelland, 72 F.3d 717, 722 (9th Cir. 1995). “An inducement consists of an opportunity plus something else—typically, excessive pressure by the government upon the defendant or the government’s taking advantage of an alternative, non-criminal type of motive.” Poehlman, 217 F.3d at 701 (citation omitted). Alvear identifies no evidence that distinguishes the FBI’s operation from a normal sting operation. Sorrells v. United States, 287 U.S. 435, 441 (1932). 4 24-6242 More importantly, the jury was presented with significant evidence of his predisposition, which “is the defendant’s willingness to commit the offense prior to being contacted by government agents, coupled with the wherewithal to do so.” Poehlman, 217 F.3d at 698; see also McClelland, 72 F.3d at 722. One of the confidential sources had been receiving unauthorized narcotics from Alvear since 2016, and the FBI began its operation only after it had learned that Alvear was illegally distributing controlled substances. Alvear also provided the drugs to the sources for money, and text messages shown to the jury revealed that other individuals had paid him for unauthorized medications, too. The video footage showed Alvear presented minimal to no reluctance when the sources requested medications. Alvear also instructed the sources and the other customers which pharmacies to use to avoid detection, demonstrating his experience and willingness to help them fill their illicit prescriptions. 3. This court “review[s] a district court’s denial of a motion for a new trial for abuse of discretion.” United States v. King, 660 F.3d 1071, 1076 (9th Cir. 2011) (citing United States v. Mack, 362 F.3d 597, 600 (9th Cir. 2004), and United States v. Allen, 341 F.3d 870, 891 (9th Cir. 2003)). A motion for a new trial is to be granted “only in exceptional cases in which the evidence preponderates heavily against the verdict.” United States v. Pimental, 654 F.2d 538, 545 (9th Cir. 1981) (citation omitted); see also Fed. R. Crim. P. 33(a). Alvear brings the same 5 24-6242 arguments he makes against the sufficiency of the evidence in support of his request for a new trial, and they fail for the same reasons. AFFIRMED. 6 24-6242
Plain English Summary
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS AUG 18 2025 MOLLY C.
Key Points
Frequently Asked Questions
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS AUG 18 2025 MOLLY C.
FlawCheck shows no negative treatment for United States v. Alvear in the current circuit citation data.
This case was decided on August 18, 2025.
Use the citation No. 10655866 and verify it against the official reporter before filing.
Why Attorneys Choose FlawFinder

Why Attorneys Choose FlawFinder

Side-by-side with Westlaw and LexisNexis

Feature FlawFinder Westlaw LexisNexis
Monthly price$19 – $99$133 – $646$153 – $399
ContractNone1–3 year min1–6 year min
Hidden fees$0, alwaysUp to $469/search$25/mo + per-doc
FlawCheck citatorIncludedKeyCite ($$$)Shepard's ($$$)
Plain-English summaryIncludedNoNo
CancelOne clickTermination feesAccount friction
Related Cases

Full legal research for $19/month

All 50 states · Federal regulations · Case law · Police SOPs · AI analysis included · No contract

Continue Researching →